[Carcino-embryogenic antigen (CEA) in patients with genital tumors (author's transl)].
The concentration of carcino-embryogenic antigen in the serum of healthy women and of patients with different benign and malignant genital tumors was determined before and after treatment. The carcino-embryogenic antigen was elevated to more than 2.5 ng/ml in 11% of the healthy control patients. Patients with carcinoma of the breast had positive CEA tests in 60%. Patients with ovarian cancer had positive CEA tests in 57%, women with carcinoma of the uterine cervix had positive tests in 50% and women with endometrial carcinoma had increased CEA levels in the serum in 38% of the cases. Following treatment the CEA values decreased.
D001943:Breast Neoplasms / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D005260:Female; D005833:Genital Neoplasms, Female / Q000276:immunology*; D006801:Humans; D010051:Ovarian Neoplasms / Q000276:immunology; D011863:Radioimmunoassay; D002583:Uterine Cervical Neoplasms / Q000276:immunology; D014594:Uterine Neoplasms / Q000276:immunology
D002272:Carcinoembryonic Antigen
Karzinoembryonales Antigen (CEA) bei Patientinnen mit Genitaltumoren.